Express Scripts’ Payer Clients On Board With Indication-Based Pricing, Exec Says
This article was originally published in The Pink Sheet Daily
PBM provides an update on its indication-based pricing project for oncology drugs, claiming it has found a way around the Medicaid “best price” dilemma.
You may also be interested in...
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.